NCT03294330View on ClinicalTrials.gov

SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 11, 2017

Primary Completion Date

September 17, 2021

Study Completion Date

November 2, 2021

Conditions

Sentinel Lymph NodeMelanoma (Skin)Breast Cancer

Interventions

DRUG

IC-Green KIT

fluorescence lymphangiography with the use of IC-Green

Trial Locations (3)

12601

Vassar Brothers Medical Center, Poughkeepsie

17033

PennState Health Milton S. Hershey Medical Center, Hershey

30322

Emory University Hospital, Atlanta

All Listed Sponsors

collaborator

Vassar Brothers Medical Center

OTHER

collaborator

Emory University

OTHER

lead

Milton S. Hershey Medical Center

OTHER

NCT03294330 - SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer | Biotech Hunter | Biotech Hunter